Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Interleukin-18 in patients with acute coronary syndromes.

Åkerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, Himmelmann A, Katus HA, Storey RF, Wallentin L, Weaver WD, Siegbahn A; PLATO Investigators.

Clin Cardiol. 2019 Oct 9. doi: 10.1002/clc.23274. [Epub ahead of print]

2.

C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes.

Andersen T, Ueland T, Ghukasyan Lakic T, Åkerblom A, Bertilsson M, Aukrust P, Michelsen AE, James SK, Becker RC, Storey RF, Wallentin L, Siegbahn A, Kontny F.

Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2402-2410. doi: 10.1161/ATVBAHA.119.312633. Epub 2019 Sep 26.

PMID:
31554419
3.

Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Åkerblom A, Wojdyla D, Steg PG, Wallentin L, James SK, Budaj A, Katus HA, Himmelmann A, Huber K, Siegbahn A, Storey RF, Becker RC; PLATO Investigators.

J Thromb Thrombolysis. 2019 Nov;48(4):563-569. doi: 10.1007/s11239-019-01938-2.

4.

Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner.

Edén D, Panagiotou G, Mokhtari D, Eriksson JW, Åberg M, Siegbahn A.

Ups J Med Sci. 2019 Aug;124(3):158-167. doi: 10.1080/03009734.2019.1645248. Epub 2019 Aug 13.

5.

Sensitive and Specific Detection of Platelet-Derived and Tissue Factor-Positive Extracellular Vesicles in Plasma Using Solid-Phase Proximity Ligation Assay.

Thulin Å, Yan J, Åberg M, Christersson C, Kamali-Moghaddam M, Siegbahn A.

TH Open. 2018 Jul 27;2(3):e250-e260. doi: 10.1055/s-0038-1667204. eCollection 2018 Jul.

6.

Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial.

Kontny F, Andersen T, Ueland T, Åkerblom A, Lakic TG, Michelsen AE, Aukrust P, Bertilsson M, Becker RC, Himmelmann A, James SK, Siegbahn A, Storey RF, Wallentin L; PLATO Investigators.

Eur Heart J Acute Cardiovasc Care. 2019 Apr 24:2048872619846334. doi: 10.1177/2048872619846334. [Epub ahead of print]

PMID:
31017470
7.

An in silico planning study comparing doses and estimated risk of toxicity in 3D-CRT, IMRT and proton beam therapy of patients with thymic tumours.

Lideståhl A, Mondlane G, Gubanski M, Lind PA, Siegbahn A.

Phys Med. 2019 Apr;60:120-126. doi: 10.1016/j.ejmp.2019.03.028. Epub 2019 Mar 30.

PMID:
31000071
8.

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.

Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002471. doi: 10.1161/CIRCGEN.119.002471. Epub 2019 Mar 21.

PMID:
30897348
9.

Subsequent Event Risk in Individuals With Established Coronary Heart Disease.

Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002470. doi: 10.1161/CIRCGEN.119.002470. Epub 2019 Mar 21.

PMID:
30896328
10.

Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes.

Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L; PLATO Investigators.

Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):294-302. doi: 10.1161/ATVBAHA.118.311042.

PMID:
30580572
11.

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial.

Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L.

Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018.

12.

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L.

JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811.

PMID:
30427997
13.

Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases.

Mondlane G, Ureba A, Gubanski M, Lind PA, Siegbahn A.

Radiat Oncol. 2018 Oct 22;13(1):206. doi: 10.1186/s13014-018-1151-6.

14.

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A.

Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12.

15.

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.

Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L.

Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.

PMID:
29871978
16.

Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams.

Mondlane G, Ureba A, Gubanski M, Lind PA, Siegbahn A.

Anticancer Res. 2018 May;38(5):2619-2625.

PMID:
29715081
17.

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.

Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF.

Eur Heart J. 2018 May 14;39(19):1672-1686f. doi: 10.1093/eurheartj/ehy066. No abstract available.

PMID:
29509886
18.

Proteomic Biomarkers for Incident Aortic Stenosis Requiring Valvular Replacement.

Ljungberg J, Janiec M, Bergdahl IA, Holmgren A, Hultdin J, Johansson B, Näslund U, Siegbahn A, Fall T, Söderberg S.

Circulation. 2018 Aug 7;138(6):590-599. doi: 10.1161/CIRCULATIONAHA.117.030414.

PMID:
29487139
19.

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.

Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA, Storey RF.

Eur Heart J. 2018 Apr 1;39(13):1078-1085. doi: 10.1093/eurheartj/ehy013.

20.

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.

Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Aukrust P, Becker RC, Bertilsson M, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Wallentin L; PLATO (Platelet Inhibition and Patient Outcomes) Trial Investigators.

J Am Heart Assoc. 2018 Jan 12;7(2). pii: e007009. doi: 10.1161/JAHA.117.007009.

21.

Quantitative evaluation of potential irradiation geometries for carbon-ion beam grid therapy.

Tsubouchi T, Henry T, Ureba A, Valdman A, Bassler N, Siegbahn A.

Med Phys. 2018 Mar;45(3):1210-1221. doi: 10.1002/mp.12749. Epub 2018 Jan 25.

PMID:
29319842
22.

The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients.

Christersson C, Lindahl B, Berglund L, Siegbahn A, Oldgren J.

Ups J Med Sci. 2017 Nov;122(4):224-233. doi: 10.1080/03009734.2017.1407849. Epub 2018 Jan 4.

23.

Methylation-based estimated biological age and cardiovascular disease.

Lind L, Ingelsson E, Sundström J, Siegbahn A, Lampa E.

Eur J Clin Invest. 2018 Feb;48(2). doi: 10.1111/eci.12872. Epub 2017 Dec 27.

PMID:
29231988
24.

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.

Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators.

Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.

25.

Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.

Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators.

J Am Heart Assoc. 2017 Oct 24;6(10). pii: e005077. doi: 10.1161/JAHA.116.005077.

26.

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G.

J Am Coll Cardiol. 2017 Oct 3;70(14):1760-1776. doi: 10.1016/j.jacc.2017.08.037. Review.

27.

Development of an interlaced-crossfiring geometry for proton grid therapy.

Henry T, Bassler N, Ureba A, Tsubouchi T, Valdman A, Siegbahn A.

Acta Oncol. 2017 Nov;56(11):1437-1443. doi: 10.1080/0284186X.2017.1350287. Epub 2017 Aug 22.

PMID:
28826311
28.

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagström E, Held C, Koenig W, Östlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, März W, Wallentin L.

J Am Coll Cardiol. 2017 Aug 15;70(7):813-826. doi: 10.1016/j.jacc.2017.06.030.

29.

GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction.

Skau E, Henriksen E, Wagner P, Hedberg P, Siegbahn A, Leppert J.

Eur J Prev Cardiol. 2017 Oct;24(15):1576-1583. doi: 10.1177/2047487317725017. Epub 2017 Aug 1.

PMID:
28762762
30.

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L.

Am Heart J. 2017 Aug;190:94-103. doi: 10.1016/j.ahj.2017.06.001. Epub 2017 Jun 6.

PMID:
28760218
31.

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.

Vedin O, Hagström E, Östlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C; STABILITY Investigators.

Int J Cardiol. 2017 Oct 15;245:271-276. doi: 10.1016/j.ijcard.2017.07.036. Epub 2017 Jul 17.

PMID:
28735759
32.

Carotid Endarterectomy Induces the Release of Inflammatory Markers and the Activation of Coagulation as Measured in the Jugular Bulb.

Kragsterman B, Bergqvist D, Siegbahn A, Parsson H.

J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2320-2328. doi: 10.1016/j.jstrokecerebrovasdis.2017.05.020. Epub 2017 Jun 23.

PMID:
28652057
33.

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time.

Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindbäck J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L.

J Am Heart Assoc. 2017 Jun 23;6(6). pii: e004851. doi: 10.1161/JAHA.116.004851.

34.

Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome.

Lowenstern A, Storey RF, Neely M, Sun JL, Angiolillo DJ, Cannon CP, Himmelmann A, Huber K, James SK, Katus HA, Morais J, Siegbahn A, Steg PG, Wallentin L, Becker RC; PLATO Investigators.

J Thromb Thrombolysis. 2017 Aug;44(2):145-153. doi: 10.1007/s11239-017-1516-y.

35.

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium, Krämer BK, Scharnagl H, Fliser D, März W, Speer T.

Lancet Diabetes Endocrinol. 2017 Jul;5(7):534-543. doi: 10.1016/S2213-8587(17)30096-7. Epub 2017 May 26.

36.

IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets.

Stojkovic S, Thulin Å, Hell L, Thaler B, Rauscher S, Baumgartner J, Gröger M, Ay C, Demyanets S, Neumayer C, Huk I, Spittler A, Huber K, Wojta J, Siegbahn A, Åberg M.

Thromb Haemost. 2017 Jun 28;117(7):1379-1390. doi: 10.1160/TH16-10-0784. Epub 2017 May 11. Erratum in: Thromb Haemost. 2017 Oct;117(10):2007.

PMID:
28492698
37.

Microparticles during long-term follow-up after acute myocardial infarction. Association to atherosclerotic burden and risk of cardiovascular events.

Christersson C, Thulin Å, Siegbahn A.

Thromb Haemost. 2017 Jul 26;117(8):1571-1581. doi: 10.1160/TH16-11-0837. Epub 2017 Apr 20.

PMID:
28424820
38.

Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L.

J Am Heart Assoc. 2017 Apr 14;6(4). pii: e005580. doi: 10.1161/JAHA.117.005580.

39.

Comparative study of the calculated risk of radiation-induced cancer after photon- and proton-beam based radiosurgery of liver metastases.

Mondlane G, Gubanski M, Lind PA, Ureba A, Siegbahn A.

Phys Med. 2017 Oct;42:263-270. doi: 10.1016/j.ejmp.2017.03.019. Epub 2017 Mar 31.

40.

Comparison of gastric-cancer radiotherapy performed with volumetric modulated arc therapy or single-field uniform-dose proton therapy.

Mondlane G, Gubanski M, Lind PA, Ureba A, Siegbahn A.

Acta Oncol. 2017 Jun;56(6):832-838. doi: 10.1080/0284186X.2017.1297536. Epub 2017 Mar 10.

PMID:
28281357
41.

Impact of physical activity on cardiovascular status in obesity.

Lind L, Carlsson AC, Siegbahn A, Sundström J, Ärnlöv J.

Eur J Clin Invest. 2017 Feb;47(2):167-175. doi: 10.1111/eci.12722.

PMID:
28036119
42.

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.

Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L; PLATO Investigators.

Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271. Epub 2016 Dec 8.

43.

Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation.

Hijazi Z, Oldgren J, Siegbahn A, Wallentin L.

Clin Chem. 2017 Jan;63(1):152-164. doi: 10.1373/clinchem.2016.255182. Epub 2016 Nov 3. Review.

44.

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.

Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER 3rd, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L; STABILITY Investigators.

Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570. Epub 2016 Nov 3.

45.

The ABC risk score for patients with atrial fibrillation - Authors' reply.

Hijazi Z, Oldgren J, Lindbäck J, Siegbahn A, Wallentin L.

Lancet. 2016 Oct 22;388(10055):1980-1981. doi: 10.1016/S0140-6736(16)31462-3. No abstract available.

PMID:
27789014
46.

A stromal cell population in the large intestine identified by tissue factor expression that is lost during colorectal cancer progression.

Eriksson O, Asplund A, Hegde G, Edqvist PH, Navani S, Pontén F, Siegbahn A.

Thromb Haemost. 2016 Nov 30;116(6):1050-1059. Epub 2016 Sep 22.

PMID:
27656710
47.

Circulating cell-derived microparticles as biomarkers in cardiovascular disease.

Thulin Å, Christersson C, Alfredsson J, Siegbahn A.

Biomark Med. 2016 Sep;10(9):1009-22. doi: 10.2217/bmm-2016-0035. Epub 2016 Sep 2. Review.

PMID:
27586235
48.

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.

Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators.

Circulation. 2016 Nov 29;134(22):1697-1707. Epub 2016 Aug 28.

PMID:
27569438
49.

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.

Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, Paré G, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Yusuf S, Wadelius M.

Pharmacogenomics. 2016 Aug;17(13):1425-39. doi: 10.2217/pgs-2016-0061. Epub 2016 Aug 4.

50.

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.

Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, López-Sendón JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L.

JAMA Cardiol. 2016 Jul 1;1(4):451-60. doi: 10.1001/jamacardio.2016.1170.

PMID:
27438322

Supplemental Content

Loading ...
Support Center